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OBSERVATIONAL STUDY

PHarmacist Avoidance or Reductions
in Medical Costs in CRITically Ill Adults:
PHARM-CRIT Study
OBJECTIVES: To comprehensively classify interventions performed by ICU clinical pharmacists and quantify cost avoidance generated through their accepted
interventions.
DESIGN: A multicenter, prospective, observational study was performed between August 2018 and January 2019.
SETTING: Community hospitals and academic medical centers in the United States.
PARTICIPANTS: ICU clinical pharmacists.
INTERVENTIONS: Recommendations classified into one of 38 intervention categories (divided into six unique sections) associated with cost avoidance.
MEASUREMENTS AND MAIN RESULTS: Two-hundred fifteen ICU pharmacists at 85 centers performed 55,926 interventions during 3,148 shifts that were
accepted on 27,681 adult patient days and generated $23,404,089 of cost avoidance. The quantity of accepted interventions and cost avoidance generated in
six established sections was adverse drug event prevention (5,777 interventions;
$5,822,539 CA), resource utilization (12,630 interventions; $4,491,318), individualization of patient care (29,284 interventions; $9,680,036 cost avoidance), prophylaxis (1,639 interventions; $1,414,465 cost avoidance), hands-on care (1,828
interventions; $1,339,621 cost avoidance), and administrative/supportive tasks
(4,768 interventions; $656,110 cost avoidance). Mean cost avoidance was $418
per intervention, $845 per patient day, and $7,435 per ICU pharmacist shift. The annualized cost avoidance from an ICU pharmacist is $1,784,302. The potential monetary cost avoidance to pharmacist salary ratio was between $3.3:1 and $9.6:1.
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CONCLUSIONS: Pharmacist involvement in the care of critically ill patients
results in significant avoidance of healthcare costs, particularly in the areas of individualization of patient care, adverse drug event prevention, and resource utilization. The potential monetary cost avoidance to pharmacist salary ratio employing
an ICU clinical pharmacist is between $3.3:1 and $9.6:1.
KEY WORDS: cost; medical care; medication; pharmacist; safety; value

A

lmost 1.5 million patients were admitted to ICUs in the United States
in 2015 (1). The costs associated with providing critical care services in
ICUs represented approximately 1% of the U.S. gross domestic product
(2). Healthcare teams in ICUs have evolved to incorporate practitioners in other
professions, including pharmacists (3). Many ICU pharmacists complete specialty residency or fellowship training and are board certified in critical care. The
role of pharmacists has shifted from preparing and dispensing medications to
performing direct patient care as a member of multidisciplinary teams. These activities have demonstrated improved clinical and financial outcomes across various patient subpopulations and hospital structures (4–9). Consequently, many
Critical Care Explorations

Copyright © 2021 The Authors.
Published by Wolters Kluwer Health,
Inc. on behalf of the Society of Critical
Care Medicine. This is an open-access
article distributed under the terms of
the Creative Commons AttributionNon Commercial-No Derivatives
License 4.0 (CCBY-NC-ND), where it
is permissible to download and share
the work provided it is properly cited.
The work cannot be changed in any
way or used commercially without
permission from the journal.
DOI: 10.1097/CCE.0000000000000594

www.ccejournal.org

    1

Rech et al

professional healthcare organizations consider pharmacists practicing in the ICU to be essential healthcare
providers, yet the participation of pharmacists in critical care units is not universal (10–13).
Previous studies of interventions performed by ICU
pharmacists have more commonly focused on adverse
drug event (ADE) prevention and reductions in medication use and costs (4–6). Although two multicenter
studies performed at the institution level and using insurance claims data evaluated a broader scope of clinical
and economic outcomes, the pharmacists’ specific interventions and roles in patient care were unknown (7, 8).
A single contemporary study at an academic medical
center evaluated a medical ICU pharmacist’s clinical
activities over a 12-month period and determined the
cost avoidance (CA) of those activities exceeded $3 million with a monetary benefit-to-cost ratio of 24.5:1 (9).
However, these findings may not be generalizable to
other ICUs and hospital settings because of the patient
population, pharmacist’s training and relationships with
providers, and rounding structure. The purposes of this
study were to comprehensively classify interventions
performed by pharmacists in the ICU and quantify CA
generated through accepted interventions.

METHODS
Study Design
The PHarmacist Avoidance or Reductions in Medical
costs in CRITically ill adults (PHARM-CRIT) study was
a multicenter, prospective, observational study that was
performed in community hospitals and academic medical centers in the United States between August 2018
and January 2019. Recruitment was performed using
electronic mail. Invitations were sent to the Society of
Critical Care Medicine’s (SCCM’s) Clinical Pharmacy
and Pharmacology section listserv. From this listserv,
which includes multiple healthcare professionals, in
addition to pharmacists, clinical pharmacists who provided direct (rounding with the ICU team) or decentralized (not directly rounding with the ICU team) patient
care for critically ill adults were eligible for study participation. Pharmacists completing residency or fellowship
were ineligible. Only interventions made by a pharmacist for patients residing in an ICU were eligible for study
inclusion. Multiple pharmacists from the same institution were eligible to participate. In order to maximize
data capture for pharmacist interventions, no minimum
2     www.ccejournal.org

or maximum duration of study participation by each
pharmacist was required; however, participants were
encouraged to document interventions for 20 shifts. All
clinical interventions made by participating pharmacists
during study participation were recorded in REDCap©
(Version 6.18.1, 2019; Vanderbilt University, Nashville,
TN) in accordance with best practices (14–16). Only
interventions for adults 18 years old or older that were
accepted were included in the analyses.
Data Collection
A comprehensive, evidence-based framework for categorizing and monetizing CA interventions by critical
care and emergency medicine pharmacists including 38
unique interventions within six intervention sections
was developed by our group a priori and previously
published (17).These interventions included direct
cost of medications (e.g., IV to oral conversions) as
well as potential CA associated with initiating drug
therapy (e.g., initiating venous thromboembolism
prophylaxis [Supplemental Table 1, http://links.
lww.com/CCX/A870]). Interventions were classified
according to 38 different intervention categorizations
organized into six different sections: ADE prevention,
resource utilization, individualization of patient care,
prophylaxis, hands-on care, and administrative and
supportive tasks. Any intervention that could not be
classified into one of the 38 intervention categories
was not recorded or available for study inclusion. All
participants received training on appropriate documentation of interventions using the CA framework.
Interventions were entered at the patient level by each
individual pharmacist. Pharmacists were encouraged
to enter these data in real time. Although all interventions (accepted and not accepted) were captured, only
interventions accepted and implemented by the medical team were included in the CA analysis. The Rush
University Medical Center Institutional Review Board
(IRB) served as the central and coordinating IRB (IRB
number 18021508-IRB01). This study was endorsed
by the SCCM’s Discovery Research Network and was
a work product of SCCM’s Clinical Pharmacy and
Pharmacology Section.
Study Outcomes and Statistical Analysis
The primary outcomes were the quantity and type of
interventions provided and the potential CA generated
December 2021 • Volume 3 • Number 12
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from clinical pharmacists practicing in ICU settings.
The values for CA overall and per patient day were
calculated by summing the CA for each intervention
based on values from our previously published systematic framework and expressed in 2019 U.S. dollars. (17, 18) A sensitivity analysis was conducted
to evaluate CA from just those interventions with
the highest quality of evidence (evidence from welldesigned controlled trials with or without randomization) according to the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE)
evidence-to-decision framework (GRADE Ia-IIb
interventions) (17). These interventions included the
following: 1) medication route: IV-to-oral conversion
(resource utilization section), 2) medication route: hypertensive crisis management (resource utilization),
3) antimicrobial therapy initiation and streamlining
(individualization of patient care), 4) change venous
thromboembolism prophylaxis to most appropriate
agent (prophylaxis), and 5) initiation of venous thromboembolism prophylaxis (prophylaxis) (17).
Descriptive statistics were used to characterize the
data. The Shapiro-Wilks test was used to determine
normality of continuous data. Normally distributed
data were expressed as mean (sd); nonnormally distributed data were expressed as median (interquartile range
[IQR])The CA per pharmacist shift value was annualized using 240 shifts, which corresponds to five shifts
per week for 48 weeks to allow for not providing care on
personal time off and holidays. This annualized CA for
a pharmacist was compared with the average pharmacist’s salary and benefits ($185,470) to calculate a monetary CA to pharmacist salary ratio (18, 19). Analyses
were performed in Stata (Version 16; StataCorp LLC,
College Station, TX).

Approximately half of each pharmacist’s shift included
prospective order verification (median, 4 hr [IQR, 0–6
hr]). ICU pharmacists most frequently rounded with a
single service (62.8%) although almost one third of participants rounded with two or more services each shift.
The median number of shifts for participating pharmacists was 17 (IQR, 6–20). ICU pharmacists cared for a
median of 15 patients each day (IQR, 12–22). Most ICU
pharmacists had been in practice for at least 1 year but
less than 12 years and were board certified (Table 1).
Of the 56,866 interventions performed by ICU
pharmacists, 55,926 (99.4%) were accepted. These
interventions were performed on 27,681 patients in six
categories: ADE prevention (accepted interventions:
5,777; percentage of total accepted interventions:
10.3%), resource utilization (12,630; 22.5%), individualization of patient care (29,284; 52.4%), prophylaxis

TABLE 1.

ICU Pharmacist Characteristics
ICU Pharmacist
(N = 215)

Characteristics
Practice areaa
Decentralized

42 (19.5)

Burn ICU

19 (8.8)

Cardiac ICU (medical)

79 (36.7)

Cardiac ICU (surgical)

87 (40.5)

Immunocompromised ICU

23 (10.7)

Medical ICU

126 (58.6)

Mixed ICU (medical/surgical)

60 (27.9)

Neuro ICU (medical/surgical)

80 (37.2)

Surgical ICU

114 (53.0)

Trauma ICU

75 (34.9)

Open ICU practice model, n (%)

RESULTS

ICU rounding 5–7 d per week, n (%)

Overall, 302 pharmacists responded to our invitation to
participate, of whom 215 participated in the study. These
215 pharmacists at 85 centers completed 3,148 shifts.
Slightly greater than half of the participating pharmacists provided care in a medical ICU (58.6%) or surgical
ICU (53.0%). More than one third of ICUs had an open
practice model, and 87.4% of the ICUs had interdisciplinary patient care rounds at least 5 days per week.
ICU pharmacists spent the majority of their shift providing direct patient care (median, 5.5 hr [IQR, 4–8 hr]).

Beds in ICU practice area,
median (IQR)

Critical Care Explorations

82 (38.1)
188 (87.4)
22 (16–27)

Nonpharmacist providers in practice
areab
Advanced practice provider

162 (75.3)

Hospitalist

55 (25.6)

Intensivist

194 (90.2)

Fellow

129 (60.0)

Resident

165 (76.7)
(Continued )
www.ccejournal.org
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TABLE 1. (Continued ).

ICU Pharmacist Characteristics
Characteristics

ICU Pharmacist
(N = 215)

Institution type, n (%)
Academic medical center

38 (44.7)

Community teaching

30 (35.3)

Community nonteaching

16 (18.8)

Government

1 (1.2)

Shift duration (hr), n (%)
8

2,452 (77.9)

10

552 (17.5)

12

51 (1.6)

Other

93 (3.0)

Shifts worked, median (IQR)

17 (6–20)

Direct patient care duration per shift
(hr), median (IQR)

5.5 (4–8)

Prospective order verification duration
per shift (hr), median (IQR)

4 (0–6)

Services rounded with each day, n (%)
0

231 (7.4)

1

1,945 (62.8)

2

653 (21.1)

3

165 (5.3)

4 or more

105 (3.4)

Patients cared for per shift (n),
median (IQR)

15 (12–22)

Years in practice (yr), n (%)
≤1

27 (12.6)

> 1 to 3

74 (34.4)

> 3 to 6

50 (23.3)

> 6 to 12

40 (18.6)

≥ 12
Board certified, n (%)

24 (11.2)
174 (81.0)

IQR = interquartile range.
a
Cumulative percentage exceeds 100% because many
pharmacists practice in multiple areas.
b
Cumulative percentage exceeds 100% because multiple
providers in practice areas and many pharmacists practice in
multiple practice areas.

(1,639; 2.9%), hands-on care (1,828; 3.3%), and administrative/supportive tasks (4,768; 8.5%). The most
frequent interventions were discontinuation of clinically unwarranted therapy (8,842; 15.8%), renal dosage adjustments in patients not receiving continuous
4     www.ccejournal.org

renal replacement therapy (CRRT) (8,557; 15.3%), initiation of nonantimicrobial therapy (7,764; 13.9%),
and antimicrobial therapy initiation and streamlining
(5,019; 9.0%). The least commonly accepted interventions were medication route for resolving shock
management (percentage accepted: 60.5%) and prevention of unnecessary high-cost medication (93.7%).
Interventions from the five most validated intervention categories used in our sensitivity analysis totaled
9,175 (16.4% of all accepted interventions) (Table 2).
The CA generated from ICU pharmacist recommendations totaled $23,404,089 in six sections: ADE
prevention (CA: $5,822,539; percentage of total CA:
24.9%), resource utilization ($4,491,318; 19.2%), individualization of patient care ($9,680,036; 41.4%), prophylaxis ($1,414,465; 6.0%), hands-on care ($1,339,621;
5.7%), and administrative/supportive ($656,110;
2.8%). The areas of greatest CA were medication
route for hypertensive crisis management ($3,436,598;
14.7%), major ADE prevention ($3,242,171; 13.9%),
and antimicrobial therapy initiation and streamlining
($3,088,944; 13.2%). In our sensitivity analysis of interventions with the highest level of evidence, CA from
the five most validated intervention categories totaled
$7,961,681 (34.0% of CA from all accepted interventions) (Table 2).
When considering all accepted interventions, average CA was $418 per intervention, $845 per patient
each day, and $7,435 per ICU pharmacist shift. The annualized CA from an ICU pharmacist was $1,784,302.
The potential monetary CA to pharmacist salary ratio
was $9.6:1. When considering accepted interventions
from the five most validated intervention categories,
average CA was $868 per intervention, $288 per patient each day, and $2,529 per ICU pharmacist shift.
Considering these categories only, the annualized CA
from an ICU pharmacist was $606,990, and the potential monetary CA to pharmacist salary ratio was $3.3:1.

DISCUSSION
This is the first multicenter prospective study to comprehensively classify interventions performed by pharmacists in adult ICUs and quantify potential CA generated
through these interventions. The CA generated from 215
pharmacists practicing in the ICU over the study period
totaled over 23 million U.S. dollars. This CA resulted
from pharmacists intervening almost 56,000 times over
December 2021 • Volume 3 • Number 12
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TABLE 2.

Accepted Pharmacist Interventions and Potential Cost Avoidance
Accepted,
n (%)

Cost
Avoidance, $

5,777 (97.9)

5,822,539

Major ADE prevention

968 (97.2)

3,242,171

Minor ADE prevention

1,894 (98.7)

772,766

170 (99.4)

569,390

Intervention
Section 1: Adverse drug event prevention

Medication reconciliation resulting in major ADE prevention
Medication reconciliation resulting in minor ADE prevention
Recommend laboratory monitoring
Section 2: Resource utilization
Preventing unnecessary laboratories and/or tests
Prevention of inappropriate screening of heparin induced thrombocytopenia
Medication route: IV to oral conversion
Medication route: hypertensive crisis management
Medication route: resolving shock management
Discontinuation of clinically unwarranted therapy
Prevention of unnecessary high-cost medication
Section 3: Individualization of patient care
Dosage adjustment: continuous renal replacement therapy
Dosage adjustment: no continuous renal replacement therapy

696 (96.8)

328,687

2,049 (98.3)

909,525

12,630 (97.9)

4,491,318

415 (98.3)

8,085

40 (97.6)

31,843

2,908 (97.6)

159,419

164 (97.6)

3,436,598

23 (60.5)

1,716

8,842 (98.3)

604,881

238 (93.7)

248,776

29,284 (98.3)

9,680,036

712 (98.5)

1,813,357

8,557 (98.6)

1,398,814

Antimicrobial therapy initiation and streamlining

5,019 (97.0)

3,088,944

Anticoagulant therapy management

1,806 (98.7)

1,262,069

Initiation of nonantimicrobial therapy

7,764 (98.2)

1,307,535

Antimicrobial pharmacokinetic evaluation

4,398 (99.1)

740,667

Total parenteral nutrition management

1,028 (99.1)

68,650

Section 4: Prophylaxis

1,639 (99.5)

1,414,465

Change venous thromboembolism prophylaxis to most appropriate agent

329 (100)

27,610

Initiation of venous thromboembolism prophylaxis

755 (99.2)

1,249,110

Initiation of stress ulcer prophylaxis

375 (99.5)

21,251

Initiation of ventilator associated pneumonia prophylaxis with chlorhexidine

180 (99.5)

116,494

Section 5: Hands-on care

1,828 (98.6)

1,339,621

1,150 (98.5)

446,798

Emergency code blue participation

213 (99.1)

327,498

Rapid response team participation

82 (97.6)

13,810

Bedside monitoring

Emergency code stroke participation

43 (100)

29,311

Emergency code sepsis participation

23 (100)

36,453

Blood factor stewardship

36 (100)

346,609

Emergency procedural sedation or rapid sequence
intubation participation

131 (99.2)

36,333

Medication teaching or discharge education

146 (97.3)

100,067

4 (100)

2,742

Culture follow-up after emergency department discharge
Antivenin stewardship

0

0
(Continued )
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TABLE 2. (Continued ).

Accepted Pharmacist Interventions and Potential Cost Avoidance
Accepted,
n (%)

Intervention
Section 6: Administrative and supportive tasks

Cost
Avoidance, $

4,768 (98.7)

656,110

2,174 (99.0)

245,836

75 (100)

31,833

Patient own medication evaluation

335 (98.5)

130,154

Therapeutic interchange

290 (98.6)

15,350

1,803 (98.4)

197,122

91 (100)

35,815

55,926 (99.4)

23,404,089

Drug information consultation
Drug information consultation: toxicology specific

Pharmacist provided drug protocol management pursuant to collaborative
practice agreement
Rejection of a restricted medication
Total

Values presented as number of accepted interventions (percentage of interventions accepted in section or subsection).

the course of greater than 27,000 patient days. In total,
99.4% of these interventions were accepted. ICU pharmacists generated $7,435 in CA per shift when all interventions were considered and $2,529 in CA per shift
when only the most validated intervention categories
were used. A significant portion of CA resulted from
interventions that individualized patient care, prevented
ADEs, and used resources more effectively. The potential
monetary CA to pharmacist salary ratio for ICU pharmacists appears to be between $3.3:1 and $9.6:1.
Major ADE prevention provided the second largest
amount of CA among the six intervention categories.
The use of multiple agents with a narrow therapeutic
index in critically ill patients with altered pharmacokinetics and pharmacodynamics places these patients at
great risk for complications (20). The significant impact
pharmacists have on ADE prevention aligns with results
from a landmark trial, which described a 66% relative
risk reduction in ADEs following inclusion of a clinical
pharmacist (5). In addition to preventing almost 3,000
ADEs during direct and decentralized patient care activities, 866 additional ADEs were prevented as a result
of interventions made following medication reconciliation. For critically ill patients, determining appropriate
medication dosages, time of last dose, presence of medications that may result in withdrawal symptoms, and
duplicative therapies are the most common interventions that prevent an ADE (21, 22).
Approximately one fifth of ICU pharmacist interventions supported more efficient utilization of
healthcare resources. Pharmacists in the ICU commonly converted more expensive IV medications
6     www.ccejournal.org

to oral dosage forms with similar efficacy or discontinue certain prophylactic medications when they are
no longer indicated. These are common practices that
often are performed pursuant to a protocol or collaborative practice agreement and can reduce ADEs
and decrease prescription costs at hospital discharge
(23, 24). Improved management of hypertensive crises was the intervention associated with the greatest
CA in this study. Additionally, antimicrobial agents
were frequently discontinued because their empirical
use was no longer necessary or a shorter duration of
use that still would adequately treat a presumed or
confirmed infection was deemed appropriate (25).
Finally, interventions that improved resource utilization also frequently reduced the use of medications
that are on shortage in the United States. These stewardship activities are imperative and challenging in
an era of medication shortages but are necessary to
maintain a medication’s stock for treating the most
critical and compelling indications and patients (26).
ICU pharmacists are well positioned to incorporate
the costs and availability of medications into the clinical decision-making process and patient care (27).
Individualizing therapies for specific patients was
the most common classification of intervention performed by ICU pharmacists, representing 52.4%
of all included interventions. These interventions
represented approximately 41% of the CA generated from ICU pharmacist recommendations. The
pharmacists’ ability to individualize antimicrobial
dosing initially and in response to pharmacokinetic and pharmacodynamic monitoring variables in
December 2021 • Volume 3 • Number 12
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patients with renal dysfunction, especially those receiving CRRT, significantly impact patient care (28).
Additionally, ICU pharmacists were active in determining the most appropriate empirical antimicrobial
therapies and de-escalating to definitive therapy or
discontinuing treatment in these complex patients.
Pharmacists are best positioned to ensure patient care
is individualized with regard to the “five rights” of
medication use: the right patient, the right drug, the
right time, the right dose, and the right route (29).
A pharmacist intervention to ensure prophylaxis
was provided for patients at risk for preventable complications of critical illness was performed infrequently,
totaling less than 3% of interventions and approximately
6% of CA. Although these interventions are not often
viewed as highly impactful, they do result in a reduced
rate of complications in high-risk patients and are processes that can be protocolized at many institutions
(23, 24). ICU pharmacists also were involved in the infrequent but highly complex activities that represent
hands-on care, which accounted for approximately 3%
of interventions and almost 6% of CA. They commonly
participated in emergency code blue (i.e., cardiac arrest)
response, which has been shown to improve compliance
with advanced cardiac life support guidelines (30, 31).
Additionally, ICU pharmacists were active in acute
stroke management, which frequently reduces door-toneedle times and increases the proportion of patients
who are eligible to receive thrombolytics (32, 33). Finally,
blood factor stewardship represented a significant portion of CA for this category of intervention. In these
activities, pharmacists ensure appropriate use of blood
factor products and dosages is achieved (34, 35). In critical and emergent situations, pharmacists bring expertise
that complement other team members and elevate the
clinical and safety outcomes for patients (36).
Fundamentally, our analysis provides estimates of
CA, but such estimates are sensitive to underlying
assumptions. We used an evidence-based framework for
the types of interventions and associated CA from published literature to classify interventions and quantify
their CA; however, these CA values are imperfect and
may result in both over- or underestimation of the true
CA, depending on the patient, pharmacist institution,
and situation (17). We used fixed costs per intervention
documented, although we acknowledge that the costs
may vary by center, participant, and other conditions
including medication costs. Specifically for categories
Critical Care Explorations

such as ADE avoidance, our approach assumed that
pharmacist interventions consistently lead to avoidance
of an adverse event that was destined to occur (i.e. 100%
probability of harm), which we recognize may not always be a valid assumption and risk overinflating CA
estimates given that an adverse event would not have
occurred or the intervention may have ultimately been
detected by another member of the healthcare team. A
recent scoping review of CA from pharmacist interventions demonstrated high risk of inflation and limited
assessment of probability of harm (38). We attempted
to mitigate this risk with the incorporation of a sensitivity analysis using only the CA categories with the
highest levels of evidence, although only five intervention categories have CA values that come from controlled studies. The results from the sensitivity analysis
that used only these intervention categories was used
to anchor the lowest suspected CA from ICU pharmacists. Although the rate and type of preventable ADEs
were determined in a similar manner to past studies, the
counterfactual or true extent of ADE development cannot be known. Participating pharmacists were encouraged to err on the side of underemphasizing the extent
of an ADE, which may have resulted in an underappreciation of the true CA from ADE prevention. In studies
of this nature, the reduction in potential harm and associated CA from an intervention is difficult to precisely
determine. In addition to a probabilistic factor that an
identified scenario actually leads to harm, the CA of an
intervention likely varies per patient, and again we used
fixed estimates for these categorizations. Nevertheless,
a substantial decrease in the quantity of accepted interventions or actual CA from these interventions would
need to occur to cause the return on investment for ICU
pharmacists demonstrated in this study to approach unacceptable values. Even for the cost estimates that were
directly quantifiable such as direct pharmaceutical costs
of agents, we recognize that costs may vary significantly
per center. Furthermore, the evidence-based framework
only included categorized interventions for which there
were pre-existing data (17). Although this framework is
based on published literature, it has not been prospectively validated with probabilistic CA considerations
included. This also implies that if an intervention was
not included as a category, we were unable to capture
activities not quantified in the framework that may still
generate CA for critically ill patients. Although categorizing CA in healthcare is a difficult task, particularly
www.ccejournal.org
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in critically ill patients, proposed guidance has recently
been published for CA studies in pharmacy practice, including a probabilistic framework (39).
There are several ways in which CA may be overestimated. In addition to the aforementioned challenges of fixed CA values, participants may have
documented accepted interventions more frequently
than accepted or inflated interventions performed, although attempts to reduce this Hawthorne effect were
instituted (37). Although selection bias was mitigated
by the diversity of pharmacists with regard to training, experience, and hospital, we cannot rule out the
possibility that pharmacists electing to participate in
the study are more likely to either make interventions
and/or document those interventions compared with
pharmacists not participating. Conversely, CA may
have been underestimated as well through a host of
factors. Additionally, the quantity and type of interventions were likely incomplete because data collection was performed in real time. A greater quantity
of interventions may have been performed than were
documented. Furthermore, sustained interaction between an ICU pharmacist and healthcare team may
alter the potential CA of a pharmacist over time. When
first incorporating an ICU pharmacist, potential CA
may be much larger as pharmacists likely have a larger
impact given protocol develop, education, implementation of best practice, and other initial benefits. This
time-varying CA of ICU pharmacists is hypothesis
generating only as we were not able to evaluate in our
study. Although many ICU clinical pharmacists were
included, these results may not be generalizable to all
ICU pharmacists and hospitals. Additionally, there
was substantial variability in the number of shifts
contributed by ICU pharmacists (IQR, 6—20); it is
unclear how this affected our findings. Finally, many
other factors may have impacted the quantity and
types of interventions as well as their acceptance, including interpersonal traits, professional relationships
with other healthcare providers, and patient volume
and complexity during the study period.

CONCLUSIONS
ICU pharmacists resulted in significant avoidance of
healthcare costs, particularly in the areas of individualization of patient care, ADE prevention, and resource
utilization. The potential monetary CA to pharmacist
8     www.ccejournal.org

salary ratio for ICU pharmacists appears to be between
$3.3:1 and $9.6:1.
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